Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis

(2015) Robert Bissonnette et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis

(2012) Jashin J. Wu et al.   ARCHIVES OF DERMATOLOGY

A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial

(2012) T.-F. Tsai et al.   BRITISH JOURNAL OF DERMATOLOGY

The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives

(2012) A.D. Burden et al.   BRITISH JOURNAL OF DERMATOLOGY

Melanoma in situ in a private practice setting 2005 through 2009: Location, lesion size, lack of concern

(2012) Sherea M. Stricklin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis

(2012) Katrina Abuabara et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

(2012) T. Tzellos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review

(2012) E. Archier et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease

(2011) Renata Micha et al.   AMERICAN JOURNAL OF CARDIOLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events

(2011) Nehal N. Mehta et al.   AMERICAN JOURNAL OF MEDICINE

The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study

(2011) K. Abuabara et al.   BRITISH JOURNAL OF DERMATOLOGY

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study

(2011) Ole Ahlehoff et al.   EUROPEAN HEART JOURNAL

Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events

(2011) Caitriona Ryan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients

(2011) Eric A. Engels et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

(2011) Rita V. Patel et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort

(2011) Marlies Wakkee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Skin cancer in solid organ transplant recipients: Advances in therapy and management

(2011) Fiona O’Reilly Zwald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis

(2011) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

(2011) David M. Pariser et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study

(2011) S. Mocellin et al.   ONCOLOGIST

Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

(2011) A. Puel et al.   SCIENCE

IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against Candida albicans

(2010) S. Kagami et al.   JOURNAL OF IMMUNOLOGY

Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis

(2010) M. S. KRATHEN et al.   JOURNAL OF RHEUMATOLOGY

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

(2010) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

(2010) S. L. Westlake et al.   RHEUMATOLOGY

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

(2009) N. N. Mehta et al.   EUROPEAN HEART JOURNAL

Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case–Control Analysis

(2009) Yolanda B. Brauchli et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Treatments for psoriasis and the risk of malignancy

(2009) Rita V. Patel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

(2009) S. L. Westlake et al.   RHEUMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET